Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
First the news: Glen Tullman, currently the CEO Transcarent, has a new, roughly $100 million venture fund, called 62 Ventures. The plan, he told me, is to use the new fund to invest in startups that fall outside the strict digital health focus of his well-known fund 7wireVentures. Among his interests will be startups from India, which Tullman called his “home away from home as a country” and where he sees great opportunity. 62 Ventures will also invest U.S.-based companies and aims to write checks between $1 million and $10 million. The fund has already invested in BridgeHealthAI, a startup aimed at “simplifying health and social benefits navigation” for people experiencing health disparities; Khyaal, a “super app” for seniors in India; and Loop Health, a health insurance and integrated care company in India.
